Balyasny Asset Management
NSRX

Balyasny Asset Management’s Nasus Pharma NSRX Stock Holding History

Balyasny Asset Management’s Portfolio NSRX Stock Details NSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99M Buy
+898,473
New +$4.64M ﹤0.01% 1781

Other funds holding NSRX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's NSRX Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Nasus Pharma (NSRX) in Q1 2026: 898,473 shares worth $1.99M. The stake represents ﹤0.01% of the portfolio and ranks #1781 among its holdings.

9 funds tracked by Wall St. Rank hold NSRX as of Q1 2026.

  • Balyasny Asset Management held 898,473 shares of Nasus Pharma worth $1.99M as of Q1 2026.
  • Nasus Pharma was a new Balyasny Asset Management position in Q1 2026.
  • Nasus Pharma made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1781 holding.
  • 9 funds tracked by Wall St. Rank held Nasus Pharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.